Earnings Estimate Revisions
搜索文档
Identiv, Inc. (INVE) Reports Q3 Loss, Beats Revenue Estimates
ZACKS· 2025-11-11 08:57
Identiv, Inc. (INVE) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +34.78%. A quarter ago, it was expected that this company would post a loss of $0.31 per share when it actually produced a loss of $0.26, delivering a surprise of +16.13%.Over the last four quarters, the company has surpas ...
Peraso (PRSO) Reports Q3 Loss, Tops Revenue Estimates
ZACKS· 2025-11-11 08:57
Peraso (PRSO) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +40.00%. A quarter ago, it was expected that this semiconductor technology company would post a loss of $0.44 per share when it actually produced a loss of $0.28, delivering a surprise of +36.36%.Over the last four quarters, the ...
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates
ZACKS· 2025-11-11 08:56
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.26%. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.5, delivering a surprise of +1.96%.Over the last four quarters, the comp ...
Rigetti Computing, Inc. (RGTI) Reports Q3 Loss, Lags Revenue Estimates
ZACKS· 2025-11-11 08:55
Rigetti Computing, Inc. (RGTI) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +40.00%. A quarter ago, it was expected that this company would post a loss of $0.06 per share when it actually produced a loss of $0.05, delivering a surprise of +16.67%.Over the last four quarters, the company ...
Vaalco Energy (EGY) Reports Q3 Loss, Lags Revenue Estimates
ZACKS· 2025-11-11 08:55
Vaalco Energy (EGY) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -150.00%. A quarter ago, it was expected that this oil and natural gas explorer would post earnings of $0.02 per share when it actually produced earnings of $0.02, delivering no surprise.Over the last four quarters, the co ...
The Beachbody Company, Inc. (BODI) Q3 Earnings and Revenues Beat Estimates
ZACKS· 2025-11-11 07:16
The Beachbody Company, Inc. (BODI) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of a loss of $0.54 per share. This compares to a loss of $1.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +194.44%. A quarter ago, it was expected that this company would post a loss of $0.93 per share when it actually produced a loss of $0.57, delivering a surprise of +38.71%.Over the last four qua ...
Red Robin (RRGB) Reports Q3 Loss, Beats Revenue Estimates
ZACKS· 2025-11-11 07:16
季度业绩表现 - 公司报告季度每股亏损0.7美元,优于Zacks共识预期的每股亏损0.78美元,相比去年同期的每股亏损1.13美元有所收窄,这代表盈利超出预期10.26% [1] - 上一季度公司实现每股收益0.26美元,远超预期的每股亏损0.25美元,盈利超出预期达204% [1] - 在过去四个季度中,公司有三次每股收益超出市场共识预期 [2] - 季度营收为2.6513亿美元,超出Zacks共识预期0.97%,但低于去年同期的2.7464亿美元 [2] - 在过去四个季度中,公司有三次营收超出市场共识预期 [2] 股价表现与市场比较 - 公司股价自年初以来已下跌约14.6%,而同期标普500指数上涨了14.4% [3] - 公司股票目前的Zacks评级为第3级(持有),预计近期表现将与市场同步 [6] 未来业绩展望 - 当前市场对下一季度的共识预期为每股亏损0.27美元,营收2.7548亿美元 [7] - 当前市场对本财年的共识预期为每股亏损0.60美元,营收12.1亿美元 [7] 行业环境与同业比较 - 公司所属的Zacks零售-餐饮行业在250多个Zacks行业中排名位于后13% [8] - 研究显示,排名前50%的行业表现优于后50%的行业,优势超过2比1 [8] - 同业公司FAT Brands Inc (FAT) 预计将在即将发布的报告中公布季度每股亏损2.43美元,较去年同期改善11.3% [9] - 过去30天内,市场对FAT Brands Inc该季度的每股收益预期保持不变 [9] - FAT Brands Inc预期营收为1.4575亿美元,较去年同期增长1.7% [9]
Quest Resource (QRHC) Reports Q3 Loss, Beats Revenue Estimates
ZACKS· 2025-11-11 07:13
Quest Resource (QRHC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.01. This compares to a loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -300.00%. A quarter ago, it was expected that this recycling company would post earnings of $0.04 per share when it actually produced a loss of $0.04, delivering a surprise of -200%.Over the last four quarters, the company has not ...
Here is Why Growth Investors Should Buy Ameriprise (AMP) Now
ZACKS· 2025-11-11 03:16
文章核心观点 - 成长型投资聚焦于财务增长高于平均水平的股票 这些股票能吸引市场关注并带来可观回报 但寻找真正的成长股具有挑战性[1] - Ameriprise Financial Services (AMP) 因其优异的增长前景和顶级Zacks评级 被推荐为具有潜力的成长股[2] - 结合A或B级增长评分和Zacks 1级或2级评级的股票 其市场表现通常更优[3] 盈利增长 - 盈利增长是吸引投资者的最关键因素 两位数增长通常意味着公司前景强劲[3] - 公司历史每股收益增长率为18.1% 但投资者更应关注其预期增长[4] - 公司今年每股收益预计增长11.3% 显著高于行业平均的8.7%[4] 现金流增长 - 对于成长型公司 高于平均水平的现金流增长至关重要 使其能够不依赖外部资金扩张业务[5] - 公司当前年同比现金流增长为7.9% 高于许多同行及行业平均的5%[5] - 公司过去3-5年的年化现金流增长率为7.3% 高于行业平均的5.4%[6] 盈利预测修正趋势 - 盈利预测修正的趋势与短期股价走势有很强的相关性 正向修正趋势是积极信号[7] - 公司当前财年的盈利预测已获上调 Zacks共识预期在过去一个月内上涨了0.5%[8] 综合评级与结论 - 基于盈利预测上调等因素 公司获得Zacks 2级评级[10] - 综合多项因素 公司获得B级增长评分 表明其是成长投资者的可靠选择[10]
Will Bausch (BHC) Gain on Rising Earnings Estimates?
ZACKS· 2025-11-11 02:21
Bausch Health (BHC) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.The upward trend in estimate revisions for this drugmaker reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends i ...